Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Fjällskog Marie Louise) "

Sökning: WFRF:(Fjällskog Marie Louise)

  • Resultat 31-40 av 51
  • Föregående 123[4]56Nästa
Sortera/gruppera träfflistan
  • Fjällskog, Marie-Louise (författare)
  • Current Medical Treatment of Endocrine Pancreatic Tumors and Future Aspects
  • 2002
  • Doktorsavhandling (övrigt vetenskapligt)abstract
    • We treated 16 patients with somatostatin analogs combined with α-interferon and achieved a biochemical and/or radiological response in 56% (median duration 22 months). We consider this treatment a good alternative for patients who fail during chemotherapy or who do not want to/cannot receive cytotoxic drugs.Thirty-six patients with neuroendocrine tumors were treated with cisplatin combined with etoposide. Of 14 patients with evaluable EPTs, 50% responded radiologically and/or biochemically (median duration 9 months). We consider this treatment useful as first-line medical treatment in aggressive EPTs or in patients failing prior chemotherapy.Twenty-eight tumor tissues from EPTs were examined with immunohistochemistry regarding expression of somatostatin receptors (ssts) 1 to 5 on tumor cells and in intratumoral vessels. We found that sst2 and sst4 were highly expressed on tumor cells and in vessels. However, sst3 and sst5 were lacking in half of the tumor tissues and in most of the vessels. Because of the variability in sst expression, we recommend analysis of each individual’s receptor expression before starting treatment.Endocrine pancreatic tumors (EPTs) are rare with an incidence of 4 per million inhabitants. In the majority of cases they grow slowly, but there are exceptions with very rapidly progressing malignant carcinomas. First-line medical treatment is streptozotocin combined with 5-fluorouracil.We examined 38 tumor samples regarding expression of tyrosine kinase receptors platelet-derived growth factor receptors (PDGFRs), c-kit and epidermal growth factor receptor (EGFR). We found that the receptors were expressed in more than half of the tumor tissues. Further studies will reveal if tyrosin kinase antagonists can be part of the future treatment arsenal.
  • Fjällskog, Marie-Louise, et al. (författare)
  • Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors
  • 2003
  • Ingår i: Medical Oncology. - 1357-0560 .- 1559-131X. ; 20:1, s. 59-67
  • Tidskriftsartikel (refereegranskat)abstract
    • Somatostatin analogs are well established in the treatment of malignant endocrine pancreatic tumors (EPTs). Our goal is to individualize their treatment using receptor-subtype-specific analogs and, therefore, exploring the receptor expression is highly important. We have examined the expression of somatostatin receptor (sst) subtypes 1–5 on tumor cells and in intratumoral vessels in 28 tumor tissues from malignant EPTs with immunohistochemistry using sst-subtype-specific polyclonal antibodies. We found that sst2 and sst4 stained positive in 90% and sst1 in 70% of the tumor tissues, whereas sst3 and sst5 stained positive in only 50% of the tumor tissues. Sst expression in intratumoral vessels was high for sst2 and sst4 (80%), moderate for sst1 (40%), and low for sst3 and sst5 (10%). The ssts were evenly distributed among the different tumor subtypes. However, tumors belonging to the same subgroup of EPTs showed a variable expression of receptor subtypes. No differences in receptor-subtype expression could be seen between poorly and well-differentiated tumors, nor between primary tumors and metastases. Prior medical treatment did not influence sst expression pattern. In conclusion, sst2 and sst4 were expressed in most tumor tissues and intratumoral vessels from EPTs. However, sst3 and sst5 were lacking in half of the tumor tissues and in most of the intratumoral vessels. These differences indicate the importance of determining each tumor’s subset of receptors before treatment with receptor-subtype-specific analogs is initiated. The importance of sst expression in intratumoral vessels is not yet known.
  • Fjällskog, Marie-Louise H., et al. (författare)
  • Treatment with Combined Streptozotocin and Liposomal Doxorubicin in Metastatic Endocrine Pancreatic Tumors
  • 2008
  • Ingår i: Neuroendocrinology. - 0028-3835 .- 1423-0194. ; 88:1, s. 53-8
  • Tidskriftsartikel (refereegranskat)abstract
    • Treatment with combined streptozotocin and liposomal doxorubicin is safe and efficient in patients with endocrine pancreatic tumors (EPTs). No cardiac toxicity was reported. BACKGROUND: The combination of streptozotocin and doxorubicin has been shown to be superior to streptozotocin and fluorouracil in the treatment of metastatic EPTs. However, the risk of cardiac toxicity from anthracyclins hampers the usefulness of the drug combination. Liposomal doxorubicin has a lower frequency of cardiac adverse events compared to doxorubicin. We wanted to assess the efficacy and safety of combined streptozotocin and liposomal doxorubicin in patients with metastatic EPTs. METHODS: Thirty patients with metastatic EPTs were recruited from three medical centers in Norway and Sweden during a time period of 3 years. All patients had histopathologically confirmed diagnoses and bidimensionally measurable lesions. 30 mg/m(2) of liposomal doxorubicin was administered on day 1 of each cycle. During the first course, 1 g of streptozotocin was given on 5 consecutive days. Thereafter, 2 g of streptozotocin was given on day 1 only. Treatment was repeated every 3 weeks. RESULTS: Twelve of 30 patients (40%) achieved an objective radiological response with a median duration of 9 months. Stabilization of disease was achieved in 17 of 30 patients (57%) for a median duration of 11 months. Only one patient had progressive disease as best response. The 2-year progression-free survival was 18% and the 2-year overall survival was 72%. The treatment was well tolerated. None of the patients experienced cardiac toxicity. CONCLUSION: We conclude that combined streptozotocin and liposomal doxorubicin is a safe and efficient treatment for EPTs. The efficacy seems to be comparable to that of combined streptozotocin and doxorubicin, whereas the cardiac toxicity clearly favors using the liposomal drug combination. 2008 S. Karger AG, Basel.
  • Fjällskog, Marie-Louise, et al. (författare)
  • Treatment of endocrine pancreatic tumors
  • 2005
  • Ingår i: Acta Oncologica. - 0284-186X .- 1651-226X. ; 44:4, s. 329-338
  • Tidskriftsartikel (refereegranskat)abstract
    • Endocrine pancreatic tumors are rare with an incidence of 4 per million inhabitants. Most tumors are malignant except for insulinomas that usually are benign. They are slowly growing in the majority of cases but there are exceptions with rapidly progressing malignant carcinomas. Because of the rarity of these tumors large randomized trials are difficult to accomplish. However, most physicians treating these patients agree that surgery should be considered in all cases and that medical treatment with chemotherapy and biotherapy is well established for this group of patients.
  • Fjällskog, Marie-Louise, et al. (författare)
  • Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas
  • 2007
  • Ingår i: Acta Oncologica. - 0284-186X .- 1651-226X. ; 46:6, s. 741-746
  • Tidskriftsartikel (refereegranskat)abstract
    • Platelet-derived growth factor receptor (PDGFR) beta signaling is involved in autocrine growth stimulation of tumor cells, tumor angiogenesis and regulation of tumor interstitial fluid pressure. Development of PDGFR antagonists has further increased the interest for PDGFR as targets for anticancer treatments. Malignant endocrine pancreatic tumors (EPTs) express PDGFR beta both in stroma and on tumor cells. To investigate the role of PDGFR beta signaling in EPTs we compared PDGFR beta expression in normal endocrine pancreas to malignant EPTs and metastases. PDGFR beta expression was examined by immunohistochemistry using specific polyclonal antibodies in ten tissue samples from normal endocrine pancreas, 21 from primary EPTs and 19 from metastases. In eight patients we compared the expression in normal endocrine pancreas to the corresponding primary tumor and metastases, in two patients normal tissue to the primary tumor and in 11 patients primary tumors to the corresponding metastases. Six of ten tissues containing normal pancreas stained negative for PDGFR beta on endocrine cells, while seven of ten stained positive in the stroma. Eighteen of 21 (86%) primary tumors stained positive for PDGFR beta on tumor cells and all had positive stroma stainings. All 19 metastases stained positive for PDGFR beta on tumor cells and in evaluable stroma (n=16). We have found that PDGFR beta is more frequently expressed in primary EPTs and metastases as compared to normal endocrine pancreatic tissue. This is also true for PDGFR beta expression in the corresponding stroma. We suggest that new therapeutic options to inhibit the growth and spread of EPTs could include targeting of PDGFR beta.
  • Granberg, Dan, et al. (författare)
  • Experience in treatment of metastatic pulmonary carcinoid tumors
  • 2001
  • Ingår i: Annals of Oncology. - 0923-7534 .- 1569-8041. ; 12:10, s. 1383-1391
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND:The only cure for patients with pulmonary carcinoids is surgery. In the present paper, we report the results of medical treatment of patients with metastatic tumors, their circulating hormone markers, and immunohistochemical profile of the tumors. PATIENTS ANDMETHODS/RESULTS:The response to systemic antitumoral treatment was studied in 31 patients with metastatic pulmonary carcinoids. Median survival from treatment start was 25 months. Alpha-interferon treatment has resulted in stable disease in 4 of 27 patients (median duration 15 months), while 23 patients showed progressive disease. Somatostatin analogues given as single drug treatment resulted in progressive disease. Streptozotocin and 5-fluorouracil resulted in progressive disease in seven of seven patients. Stable disease was obtained for 8 and 10 months respectively in two of two patients treated with streptozotocin + doxorubicin. Two of eight patients treated with cisplatinum + etoposide showed a significant decrease in tumor size lasting six and eight months respectively, and one displayed stable disease for seven months. Elevation of plasma chromogranin A was seen in 93%.CONCLUSIONS:The results of systemic antitumoral treatment of pulmonary carcinoids with distant metastases are generally discouraging. Chemotherapy with cisplatinum + etoposide, or doxorubicin combined with streptozotocin or paclitaxel may be of value. Alpha-interferon and octreotide offer efficient symptomatic relief, but stabilizes tumor growth in merely 15% of the cases. Plasma chromogranin A is the most frequently elevated tumor marker.
  • Grönberg, Malin, 1980-, et al. (författare)
  • Expression of ghrelin is correlated to good outcome in invasive breast cancer
  • ????
  • Annan publikation (populärvet., debatt m.m.)abstract
    • Purpose: Expression of the peptide hormones ghrelin and obestatin has previously been demonstrated in human mammary glands. However, the clinical implications of the expression of these peptides in breast cancer are unclear. The aim of this study was to investigate the potential clinical value of ghrelin and obestatin as breast cancer biomarkers.Experimental Design: A tissue microarray containing breast cancer specimens from 144 patients was immunostained with antibodies versus ghrelin and obestatin. The expression of the two peptides was evaluated and correlated to previously known prognostic factors in breast cancer and to the outcome. Cox-regression analysis was used to assess whether these markers may predict survival status of breast cancer patients.Results: Moderate to strong immunoreactivity for ghrelin and obestatin was observed in 71.5% and 77.1% of the cases, respectively. Ghrelin and obestatin expression was significantly but weakly correlated to low histological grade, estrogen receptor positivity, small tumor size and low proliferation. In both uni- and multivariate analyses ghrelin expression was correlated to significantly better recurrence-free and breast cancer-specific survival. Reproducibility between the two readers was very good for both stainings with kappa values of 0.94-1.00.Conclusion: Patients with tumors expressing ghrelin had 2-3 times lower risk for recurrence or breast cancer death than those lacking ghrelin expression. Ghrelin expression is easily assessable with high reproducibility using immunohistochemistry. Further investigations are needed to establish the clinical significance of ghrelin as a biomarker in breast cancer.
  • Grönberg, Malin, et al. (författare)
  • Ghrelin expression is associated with a favorable outcome in male breast cancer
  • 2018
  • Ingår i: Scientific Reports. - NATURE PUBLISHING GROUP. - 2045-2322 .- 2045-2322. ; 8
  • Tidskriftsartikel (refereegranskat)abstract
    • Ghrelin and obestatin are two gastrointestinal peptides, derived from a common precursor. Expression of both peptides have been found in breast cancer tissue and ghrelin has been associated with breast cancer development. Ghrelin expression is associated with longer survival in women diagnosed with invasive and node negative breast cancer. The clinical implications of the peptide expression in male breast cancer are unclear. The aim of this study was to investigate the role and potential clinical value of ghrelin and obestatin in male breast cancer. A tissue microarray of invasive male breast cancer specimens from 197 patients was immunostained with antibodies versus the two peptides. The expression of the peptides was correlated to previously known prognostic factors in breast cancer and to the outcome. No strong correlations were found between ghrelin or obestatin expression and other known prognostic factors. Only ghrelin expression was statistically significantly correlated to breast cancer-specific survival (HR 0.39, 95% CI 0.18-0.83) in univariate analyses and in multivariate models, adjusted for tumor size and node status (HR 0.38, 95% CI 0.17-0.87). HR for obestatin was 0.38 (95% CI 0.11-1.24). Ghrelin is a potential prognostic factor for breast cancer death in male breast cancer. Patients with tumors expressing ghrelin have a 2.5-fold lower risk for breast cancer death than those lacking ghrelin expression. Drugs targeting ghrelin are currently being investigated in clinical studies treating metabolic or nutritional disorders. Ghrelin should be further evaluated in forthcoming studies as a prognostic marker with the aim to be included in decision algorithms.
  • Grönberg, Malin, et al. (författare)
  • Ghrelin is a prognostic marker and a potential therapeutic target in breast cancer
  • 2017
  • Ingår i: PLoS ONE. - 1932-6203 .- 1932-6203. ; 12:4
  • Tidskriftsartikel (refereegranskat)abstract
    • Ghrelin and obestatin are gastrointestinal peptides, encoded by the same preproghrelin gene. Both are expressed in breast cancer tissue and ghrelin has been implicated in breast cancer tumorigenesis. Despite recent advances in breast cancer management the need for new prognostic markers and potential therapeutic targets in breast cancer remains high. We studied the prognostic impact of ghrelin and obestatin in women with node negative breast cancer. Within a cohort of women with breast cancer with tumor size <= 50 mm, no lymph node metastases and no initiation of adjuvant chemotherapy, 190 women were identified who died from breast cancer and randomly selected 190 women alive at the corresponding time as controls. Tumor tissues were immunostained with antibodies versus the peptides. Ghrelin expression was associated with better breast cancer specific survival in univariate analyses (OR 0.55, 95% CI 0.36-0.84) and in multivariate models, adjusted for endocrine treatment and age (OR 0.57, 95% CI 0.36-0.89). Obestatin expression was non-informative (OR 1.2, 95% CI 0.60-2.46). Ghrelin expression is independent prognostic factor for breast cancer death in node negative patients-halving the risk for dying of breast cancer. Our data implies that ghrelin could be a potential therapeutic target in breast cancer treatment.
Skapa referenser, mejla, bekava och länka
  • Resultat 31-40 av 51
  • Föregående 123[4]56Nästa
fritt online (13)
Typ av publikation
tidskriftsartikel (43)
annan publikation (3)
doktorsavhandling (2)
forskningsöversikt (2)
konferensbidrag (1)
Typ av innehåll
refereegranskat (39)
övrigt vetenskapligt (10)
populärvet., debatt m.m. (2)
Fjällskog, Marie Lou ... (48)
Blomqvist, Carl, (18)
Amini, Rose-Marie, (15)
Ahlin, Cecilia, (15)
Nilsson, Cecilia, (11)
Hedenfalk, Ingrid, (10)
visa fler...
Holmqvist, Marit (9)
Holmberg, Lars, (8)
Jirström, Karin, (8)
Wärnberg, Fredrik, (7)
Zhou, Wenjing, (7)
Nordin, Karin, (6)
Ringnér, Markus, (6)
Tiensuu Janson, Eva, (6)
Arving, Cecilia, (6)
Johansson, Ida, (6)
Fernö, Mårten, (5)
Eriksson, Barbro, (5)
Fjallskog, ML (4)
Janson, Eva Tiensuu, (4)
Forsare, Carina, (4)
Janson, Eva T., (4)
Nevanlinna, Heli (3)
Malmström, Per, (3)
Öberg, Kjell, (3)
Grönberg, Malin, (3)
Bergkvist, Leif, (3)
Thorstenson, Sten, (3)
Sollie, Thomas (3)
Aaltonen, Kirsimari (2)
Ferno, Marten, (2)
Bendahl, Pär Ola, (2)
Rydén, Lisa, (2)
Peterson, Magnus, 19 ... (2)
Ringberg, Anita (2)
Abdsaleh, Shahin, (2)
Johansson, Christine ... (2)
Ahlgren, Johan, (2)
Tolockiene, Egle, (2)
Bergh, Jonas (2)
Andersson, Gerhard, (2)
Grabau, Dorthe, (2)
Nilsson-Ihrfelt, Eli ... (2)
Lauss, Martin, (2)
Luts, Lena, (2)
Staaf, Johan, (2)
Berglund, Pontus, (2)
Klintman, Marie, (2)
Holmström, Inger K., (2)
Tot, Tibor, (2)
visa färre...
Uppsala universitet (49)
Lunds universitet (17)
Linköpings universitet (7)
Karolinska Institutet (5)
Mälardalens högskola (2)
Örebro universitet (2)
visa fler...
Umeå universitet (1)
visa färre...
Engelska (45)
Svenska (2)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (49)
Samhällsvetenskap (3)


pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy